FP 045

Drug Profile

FP 045

Alternative Names: FP-045

Latest Information Update: 29 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Foresee Pharmaceuticals
  • Class Hepatoprotectants; Small molecules
  • Mechanism of Action Aldehyde dehydrogenase 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis

Most Recent Events

  • 05 Apr 2017 Preclinical trials in Cardiovascular disorders in Taiwan, USA (PO)
  • 05 Apr 2017 Preclinical trials in Non-alcoholic fatty liver disease in USA, Taiwan (PO)
  • 05 Apr 2017 Preclinical trials in Non-alcoholic steatohepatitis in USA, Taiwan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top